Overview

Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
That anti-TNF therapy and rituximab therapy are equally effective in treating patients with rheumatoid arthritis who meet the eligibility criteria for biologic therapy in the British Society for Rheumatology guidelines, and have not previously been exposed to biologic therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Glasgow
Collaborators:
Arthritis Research UK
NHS Borders
NHS Fife
NHS Grampian
NHS Lothian
NHS Tayside
Treatments:
Adalimumab
Etanercept
Rituximab